CATHETER PRECISION INC (VTAK)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$0.21+6.82%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · VTAK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.7% |
| Our one-year growth estimate | diamond | 100.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 189.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 88 industry peers · Company calendar date is not available
VTAK — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-07-31
Unregistered Sales of Equity Securities. On July 30, 2026, Catheter Precision, Inc. (the “Company”) consummated the closing (the “Series C-4 Closing”) of the sale and issuance of an aggregate of 2,821 shares of the Company’s Series C-4 Convertible Preferred Stock, par value $0.0001 per share and stated value of $1,000 per share (the “Series C-4 Preferred Stock”), for aggregate gross proceeds of $2,821,000.00. The Series C-4 Preferred Stock was issued pursuant to the exercise by certain invest…
Why it matters: Higher gross profit margins show the company can make more money.
Supportive ifGross profit margin improves further from the current level of 90.7%.
Worry ifGross profit margin declines or remains flat.
Why it matters: Higher gross profit shows better cost control and product acceptance.
Supportive ifGross profit exceeds $390,000 in Q2 2026.
Worry ifGross profit falls below $350,000 in Q2 2026.
Why it matters: More aircraft would indicate strong growth potential for the aviation segment.
Supportive ifAnnouncement of the addition of at least 2 more aircraft to the Flyte fleet.
Worry ifNo announcement of fleet expansion or delays in adding aircraft.
Why it matters: New clinical publications would show the value of the technologies. This would help more people use them.
Supportive ifMore peer-reviewed publications support VIVO and LockeT. This is good news.
Worry ifThere were no new clinical publications. No bad news came out about VIVO and LockeT.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$351 on $10,000 · ±3.5% | How much price usually moves either way. |
| Bad day | $1,189 loss on $10,000 · 11.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,345 loss on $10,000 · 93.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This would confirm strong momentum in revenue growth following the 200% increase in Q1.
Supportive ifQ2 revenue was over $1 million. This shows continued growth.
Worry ifQ2 revenue reported below $1 million, suggesting growth may be slowing.
Why it matters: This would show how well the Flyte acquisition can grow and make money.
Supportive ifFlyte successfully scales its fleet to 5 aircraft by the end of Q2 2026.
Worry ifThe fleet has 3 aircraft. This shows slow growth in aviation.
Why it matters: A smaller net loss would show better financial health and efficiency.
Supportive ifNet loss was below $1.5 million for Q2. This shows continued improvement.
Worry ifNet loss is still above $1.5 million. This suggests ongoing financial issues.